长春高新：关于子公司绒促卵泡激素αN02注射液在境内获批上市的公告

Core Points - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for its application of αN02 injection of follicle-stimulating hormone, which has been approved for marketing in China [1] Company Summary - The approval of the αN02 injection marks a significant milestone for Changchun Jinsai Pharmaceutical, enhancing its product portfolio in the pharmaceutical market [1] - This development indicates the company's commitment to expanding its presence in the biopharmaceutical sector [1] Industry Summary - The approval of new drugs like αN02 injection reflects the ongoing growth and regulatory advancements within the pharmaceutical industry in China [1] - The successful registration of this drug may lead to increased competition and innovation in the reproductive health segment of the pharmaceutical market [1]